IN Brief:
- AstraNu closed a $3.5m seed round led by Celesta Capital with investment from the New Jersey Innovation Evergreen Fund.
- The company claims its chip-scale swept-source OCT engine is more than ten times smaller than conventional swept-source equipment.
- Funding is directed towards engineering hires, partner testing and manufacturing readiness, not an announced production launch.
AstraNu has raised $3.5 million in seed funding to advance its chip-scale swept-source optical coherence tomography (OCT) imaging engine towards integration into medical equipment. Celesta Capital led the round, with investment from the New Jersey Innovation Evergreen Fund. The company plans to expand its photonics team, evaluate the engine with equipment partners and prepare its manufacturing process; the funding announcement does not establish a date for volume deliveries.
The New Jersey company emerged from Nokia Bell Labs in May 2025 after research into compact OCT architectures. OCT is an interferometric imaging technique that compares light returning from a sample with a reference signal to build depth-resolved pictures of tissue. It is established in retinal imaging, while its use in other medical systems depends on the optics, measurement range and processing requirements of the particular instrument.
In swept-source OCT, a wavelength-tunable light source scans across a range of optical frequencies. Light returned from the sample is compared with a reference path, and the resulting interference signal is processed to reconstruct internal structure. The arrangement differs from spectral-domain OCT systems that use a broadband source and spectrometer to measure the interference spectrum. Optical bandwidth, sweep stability, detection sensitivity and processing are among the parameters that influence achievable imaging performance.
Swept-source OCT systems offer useful imaging speeds and depth characteristics in some applications, but traditionally require a tuneable source, optical components and associated control electronics that take up considerable space. AstraNu says its engine is more than ten times smaller than conventional swept-source systems and is intended to approach the cost of spectral-domain OCT. Those are company comparisons: no independently verified dimensions, purchase price, imaging speed or resolution benchmark is supplied alongside the funding announcement.
AstraNu is targeting medical-device, imaging and optics manufacturers that could incorporate the engine as a subsystem in their own products. The distinction between an imaging engine and an approved medical device is significant at the engineering level. Optical coupling, power supply design, temperature control, signal acquisition and clinical software still have to operate as an integrated instrument, which its manufacturer must validate for the intended medical application.
The company says it has demonstrated swept-source behaviour in a compact architecture and is moving into partner testing. In an interview published alongside the investment, AstraNu president and general manager Kevin Blalock described the company’s plans for smaller systems, including a handheld format. The interview concerns development ambitions rather than completed approvals, validated diagnostic performance or confirmed shipment volumes.
Manufacturing preparation will require the photonic and electronic assemblies to deliver consistent behaviour beyond the first working prototypes. The wavelength sweep, optical losses, alignment and detector performance all influence the interference signal and the processed image. Production test methods must be able to identify units that fall outside the specifications agreed with a device manufacturer, while component sourcing and packaging will affect how reliably those results can be reproduced.
Ophthalmology is AstraNu’s initial commercial focus, with possible applications elsewhere in medicine also being explored. Smaller OCT subsystems could alter the size or physical arrangement of an eye-imaging instrument, although the remaining optics, scanners and display electronics also determine the dimensions of a completed product. The company has not announced clinical study results or regulatory clearance for an instrument using the engine.
The funding round also reflects the route through which the technology reached a company. Nokia Bell Labs developed the underlying approach, and Celesta supported the spin-out as a commercialisation project. Continued backing from an existing investor and a state innovation fund gives AstraNu resources for the next engineering steps; it does not remove the need for evidence from device partners or establish a date for finished instruments.
For partner evaluations, optical imaging companies will need enough information about the engine’s output, electrical interfaces and operating limits to assess integration with existing instruments. The investment supports that testing alongside work on manufacturing readiness. AstraNu has not identified customers that have committed to a production programme, and the announcement should not be interpreted as evidence that medical equipment incorporating the module is already on the market.
The next disclosed activities are expansion of the engineering team, evaluation with medical-device partners and preparation of the manufacturing supply chain. Those steps follow the $3.5 million financing and will determine how the claimed reductions in size and cost hold up in integrated equipment. Comparative technical performance and a commercial release timetable have not been published.


